Literature DB >> 19821090

The effect evaluation of highly active antiretroviral therapy to patients with AIDS in Hubei province of China.

Xuehua Li1, Yihua Xu, Shaofa Nie, Hao Xiang, Chongjian Wang.   

Abstract

The effects of highly active antiretroviral therapy (HAART) to patients with AIDS in Hubei province of China were investigated in order to provide scientific evidence to reinforce the management of HAART. Self-made questionnaires and descriptive method of epidemiology were used to collect and describe the changes of clinical symptoms, HIV RNA concentration, and immune function of patients with AIDS. After HAART, the effective rate of fever, cough, diarrhea, lymphadenectasis, weight loss, tetter, debility and fungous infection was 92.4%, 90.85%, 92.91%, 90.73%, 93.69%, 89.04%, 92.34%, and 83.1%, respectively. Of 117 patients with detected HIV RNA concentration, 41.03% had declined over 0.5 log, and 52.99% less than 0.5 log. CD4(+)T cell count was obviously increased: the average number after HAART for 3 or 6 months was 237/microL (26-755/microL) and 239/microL (17-833/microL), respectively. HAART can improve AIDS patients' clinical symptoms, reduce HIV RNA concentration, and maintain immune function. It is very important for the effectiveness of HAART to raise clinical adherence of patients with AIDS and have a persistent surveillance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821090     DOI: 10.1007/s11596-009-0510-9

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

1.  Viral load trend in HIV-1 seropositive patients with different CD4 cell counts before starting HAART.

Authors:  M C Re; E Ramazzotti; R Manfredi; G Furlini; M Vignoli; C Maldini; M Borderi; M La Placa
Journal:  J Clin Virol       Date:  2000-06       Impact factor: 3.168

Review 2.  Update on HAART in HIV.

Authors:  Patrick Yeni
Journal:  J Hepatol       Date:  2005-11-28       Impact factor: 25.083

3.  HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals.

Authors:  Davide Gibellini; Marco Borderi; Elisa De Crignis; Ronny Cicola; Laura Cimatti; Francesca Vitone; Francesco Chiodo; Maria Carla Re
Journal:  J Infect       Date:  2008-02-13       Impact factor: 6.072

4.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

Authors:  N G Pakker; D W Notermans; R J de Boer; M T Roos; F de Wolf; A Hill; J M Leonard; S A Danner; F Miedema; P T Schellekens
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

5.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Authors:  D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

6.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  HIV transmission risk behavior and its relation to antiretroviral treatment adherence.

Authors:  Rachel C Flaks; William J Burman; Patrick J Gourley; Cornelis A Rietmeijer; David L Cohn
Journal:  Sex Transm Dis       Date:  2003-05       Impact factor: 2.830

8.  Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

Authors:  Federico Pulido; Jose R Arribas; Jose M Miró; María A Costa; Juan González; Rafael Rubio; Jose M Peña; Miguel Torralba; Montserrat Lonca; Alicia Lorenzo; Concepcion Cepeda; Juan J Vázquez; Jose M Gatell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-01       Impact factor: 3.731

9.  Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru.

Authors:  Diego López de Castilla; Kristien Verdonck; Larissa Otero; David Iglesias; Juan Echevarría; Lynen Lut; Eduardo Gotuzzo; Carlos Seas
Journal:  Int J Infect Dis       Date:  2008-05       Impact factor: 3.623

10.  Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Authors:  Jean-Jacques Parienti; Véronique Massari; Diane Descamps; Astrid Vabret; Elisabeth Bouvet; Bernard Larouzé; Renaud Verdon
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

View more
  3 in total

1.  Correlation analysis on total lymphocyte count and CD4 count in HIV-infected patients: a retrospective evaluation.

Authors:  Yuming Wang; Shuying Liang; Erman Yu; Jinling Guo; Zizhao Li; Zhe Wang; Yukai Du
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

2.  Rates and risk factors associated with the progression of HIV to AIDS among HIV patients from Zhejiang, China between 2008 and 2012.

Authors:  Lin Chen; Jiezhe Yang; Renjie Zhang; Yun Xu; Jinlei Zheng; Jianmin Jiang; Jun Jiang; Lin He; Ning Wang; Philip Chun Yeung; Xiaohong Pan
Journal:  AIDS Res Ther       Date:  2015-09-25       Impact factor: 2.250

3.  Determinants of progression to AIDS and death following HIV diagnosis: a retrospective cohort study in Wuhan, China.

Authors:  Hongbo Jiang; Nianhua Xie; Beibei Cao; Li Tan; Yunzhou Fan; Fan Zhang; Zhongzhao Yao; Li Liu; Shaofa Nie
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.